These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21354201)

  • 21. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test.
    D'Aquila PS; Panin F; Serra G
    Eur J Pharmacol; 2004 May; 492(1):61-3. PubMed ID: 15145707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms.
    Chae Y; Yeom M; Han JH; Park HJ; Hahm DH; Shim I; Lee HS; Lee H
    Neurosci Lett; 2008 Jan; 430(2):98-102. PubMed ID: 18060697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
    Matsushita N; Misu Y; Goshima Y
    Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion.
    Semba J; Wakuta M
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):435-41. PubMed ID: 18778441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotine increases ethanol preference but decreases locomotor activity during the initial stages of chronic ethanol withdrawal.
    Lallemand F; Ward RJ; De Witte P
    Alcohol Alcohol; 2007; 42(3):207-18. PubMed ID: 17526630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule.
    Malmlöf T; Svensson TH; Schilström B
    Exp Neurol; 2008 Aug; 212(2):538-42. PubMed ID: 18561915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms.
    Hildebrand BE; Nomikos GG; Bondjers C; Nisell M; Svensson TH
    Psychopharmacology (Berl); 1997 Feb; 129(4):348-56. PubMed ID: 9085404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models of nicotine withdrawal: intracranial self-stimulation and somatic signs of withdrawal.
    Bauzo RM; Bruijnzeel AW
    Methods Mol Biol; 2012; 829():257-68. PubMed ID: 22231819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypericum perforatum attenuates nicotine withdrawal signs in mice.
    Catania MA; Firenzuoli F; Crupi A; Mannucci C; Caputi AP; Calapai G
    Psychopharmacology (Berl); 2003 Sep; 169(2):186-9. PubMed ID: 12719964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nicotine withdrawal in selectively bred high and low nicotine preferring rat lines.
    Nesil T; Kanit L; Ugur M; Pogun S
    Pharmacol Biochem Behav; 2015 Apr; 131():91-7. PubMed ID: 25687373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
    Cryan JF; Bruijnzeel AW; Skjei KL; Markou A
    Psychopharmacology (Berl); 2003 Jul; 168(3):347-58. PubMed ID: 12698231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible.
    Malin DH; Lake JR; Payne MC; Short PE; Carter VA; Cunningham JS; Wilson OB
    Pharmacol Biochem Behav; 1996 Jan; 53(1):81-5. PubMed ID: 8848464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.